Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.